CDKN2A and non-small cell lung carcinoma: In the TCGA dataset (TCGA, Provisional), 177 out of 283 (62.5%) stage I/II NSCLC patients showed CDKN2A mutation, and the median relapse-free survival (RFS) was 37.65 months in the CDKN2A-altered patients and 38.37 months in the CDKN2A normal patients (p = 0.5676).